Ellodi Pharmaceuticals is developing targeted therapies for Eosinophilic Esophagitis, a chronic inflammatory condition affecting the esophagus. Their approach focuses on addressing the underlying inflammation to improve patient outcomes and quality of life.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus that causes difficulty swallowing, food impaction, and other gastrointestinal issues, significantly impacting patients' quality of life. Current treatments often fail to address the underlying inflammation effectively, leading to persistent symptoms and the need for repeated interventions.
Solution
Ellodi Pharmaceuticals is developing targeted therapies designed to treat the underlying causes of Eosinophilic Esophagitis. Their approach focuses on novel mechanisms to resolve esophageal inflammation, prevent disease progression, and alleviate the symptoms associated with EoE. By targeting the specific pathways involved in the inflammatory cascade, Ellodi aims to provide more effective and durable relief for patients suffering from this chronic condition. Their lead compound, APT-1011, is currently under investigation in clinical trials to evaluate its safety and efficacy in treating EoE.
Target Audience
The primary target audience includes gastroenterologists and patients diagnosed with Eosinophilic Esophagitis, as well as their caregivers.
Features
- APT-1011: A novel therapeutic in development for Eosinophilic Esophagitis
- Focus on resolving esophageal inflammation
- Pipeline includes targeted therapies for EoE
- Investigating mechanisms to prevent disease progression
- Clinical trials underway to evaluate safety and efficacy